NICE decides Abraxane will not be available on the NHS

The National Institute for Health and Care Excellence (NICE) has ruled in the last month that pancreatic cancer drug Abraxane should not be provided on the NHS because while more effective than one of the currently approved pancreatic cancer treatments it is associated with more serious side effects and is also more expensive.

For full details of the story please click here. (Original Article,, 30/12/2014)

Further details on Abraxane are available from MacMillan.

Posted in Pancreatic Cancer.